Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — Technical Presentation (October 2026)
34 slides from Eyepoint's technical presentation, Oct 19, 2026
Slide 1: LUCIA Phase 3 Clinical Trial DURAVYU in Wet AMD Topline Results
LUCIA Phase 3 Clinical Trial DURAVYU in Wet AMD Topline Results | October 2026 Exhibit 99.2
Slide 2: Legal Disclaimers
Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, even
Slide 3: Introduction
@ EvePoint Introduction _
Slide 4: Overview of DURAVYU Development Program
Overview of DURAVYU Development Program Follows non-inferiority pathway of five most recent FDA approvals in wet AMD Note: Timeline not to scale. AMD: age-related macular degeneration; DME: diabetic macular edema; q24W, every 24 weeks; q8W, every 8 weeks. Wet AMD DURAVYU single injection, dose-escal
Slide 5: The DURAVYU Advantage: A Differentiated Program in Retina
The DURAVYU™ Advantage: A Differentiated Program in Retina 1. Data from preclinical studies. Following a single DURAVYU 900 µg dose in Dutch-Belted rabbits, vorolanib reached concentrations exceeding IC50 in the choroid and retina within hours of administration. 2. Wykoff CC, et al. J Vitreoretin Di
Slide 6: Summary
Summary AMD, age-related macular degeneration; Diabetic Macular Edema, DME. LUCIA did not meet primary endpoint of mean change in BCVA, despite visual improvement Meaningful reduction in treatment burden (nominal p-value <0.0001) with strong anatomic control demonstrates activity of DURAVYU Continue
Slide 7: Phase 3 Wet AMD Program LUGANO and LUCIA Pivotal Trials
Phase 3 Wet AMD Program LUGANO and LUCIA Pivotal Trials
Slide 8: LUGANO & LUCIA Follow Established Non-Inferiority Regulatory Path in Wet AMD
LUGANO & LUCIA Follow Established Non-Inferiority Regulatory Path in Wet AMD Endpoints Primary Endpoint: Non-inferior (NI) mean change in BCVA from Day 1 to Week 52 and Week 56 (blended) vs aflibercept control (NI margin of -4.5 letters) Key Secondary Endpoints: Safety Reduction in treatment burden
Slide 9: Pivotal Phase 3 Program Follows Established Non-Inferiority Regulatory Pathway
Pivotal Phase 3 Program Follows Established Non-Inferiority Regulatory Pathway *> 5 letter drop with 75 microns new fluid from AMD compared to best on study, or new, sight threatening hemorrhage due to wet AMD DURAVYU dosing consists of 2 inserts delivered in a single injection. D, day; W, week; EOS
Slide 10: LUCIA Topline Results Baseline Characteristics
LUCIA Topline Results Baseline Characteristics
Slide 11: LUCIA Baseline Characteristics
LUCIA Baseline Characteristics Preliminary data – pending final analysis DURAVYU 2.7mg (n=232) Aflibercept 2mg q8W (n=238) Age (years), mean (SD) 76.8 (8.4) 77.2 (8.5) ≥ 65, n (%) 215 (92.7) 217 (91.2) Female, n (%) 144 (62.1) 129 (54.2) Treatment Naïve, n (%) 176 (75.9) 179 (75.2) Previousl
Slide 12: LUCIA Topline Results Visual Acuity
LUCIA Topline Results Visual Acuity
Slide 13: Primary Endpoint: Mean Change in BCVA from Baseline
Primary Endpoint: Mean Change in BCVA from Baseline Preliminary data – pending final analysis LS Mean Change in ETDRS letters Mean Change in BCVA from Baseline Study visit, weeks Aflibercept 2 mg q8W +6.1 letters DURAVYU 2.7 mg q24W +2.5 letters Difference -3.7 letters *Blended week 52 and week 56 c
Slide 14: LUCIA Topline Results Reduction in Treatment Burden & Supplement-Free Rates
LUCIA Topline Results Reduction in Treatment Burden & Supplement-Free Rates
Slide 15: Meaningful Treatment Burden Reduction
Average Supplements in DURAVYU patients1 Meaningful Treatment Burden Reduction Preliminary data – pending final analysis Total Injections* After Loading Doses (Avg.) 1. Approximately 1.3 average supplemental injection annualized *Participants who discontinued treatment or study early without any Wee
Slide 16: Supplement-Free Rates Demonstrate DURAVYU's Durability
Supplement-Free Rates Demonstrate DURAVYU’s Durability Preliminary data – pending final analysis DURAVYU 2.7mg Up to Week 32 Up to Week 56 Supplement-Free Patients 70% 52% Patients with 0 or 1 Supplement 94% 71% Patients with 2 or fewer Supplements 99.6% 83% Note: For DURAVYU group: the number of in
Slide 17: LUCIA Topline Results Anatomic Control
LUCIA Topline Results Anatomic Control
Slide 18: Anatomic Results Demonstrate Fluid Control
Anatomic Results Demonstrate Fluid Control LS, least squares; CST, central subfield thickness; q24W, every 24 weeks; q8W, every 8 weeks. Preliminary data – pending final analysis LS Mean Change in CST, in microns Mean Change in CST from Baseline Through Week 56 Study visit, weeks Aflibercept 2 mg q8
Slide 19: LUCIA Topline Results Safety Data
LUCIA Topline Results Safety Data
Slide 20: DURAVYU Favorable Safety Profile With Repeat Dosing
DURAVYU Favorable Safety Profile With Repeat Dosing No cases of: Insert migration into the anterior chamber Anterior chamber opacities Free-floating particles Retinal vasculitis (occlusive or non-occlusive) AEs of particular interest – all <1% in both arms: Severe intraocular inflammation Endophthal
Slide 21: Subjects with Ocular AEs in Study Eye ≥2%
Subjects with Ocular AEs in Study Eye ≥2% through Week 56 DURAVYU 2.7mg (n=232) Aflibercept 2mg (n=243) Conjunctival haemorrhage 9.1% 3.7% Vitreous floaters 8.2% 2.1% Cataract 4.7% 5.3% Neovascular age-related macular degeneration 4.7% 2.1% Retinal haemorrhage 4.7% 1.2% Posterior caps
Slide 22: Pooled Results LUGANO and LUCIA
Pooled Results LUGANO and LUCIA
Slide 23: Pooled Treatment Burden Reduction is Meaningful
Average Supplements in DURAVYU patients1 Pooled Treatment Burden Reduction is Meaningful Preliminary data – pending final analysis Total Injections* After Loading Doses (Avg.) 5.3 3.2 Treatment Burden Reduction achieving superiority to on-label aflibercept (maximum 60%) 40% Fewer Injections on avera
Slide 24: Pooled Anatomic Results Demonstrate Fluid Control
Pooled Anatomic Results Demonstrate Fluid Control Preliminary data – pending final analysis LS Mean Change in CST, in microns Mean Change in CST from Baseline Through Week 56 Study visit, weeks Aflibercept 2 mg q8W -79 µm DURAVYU 2.7 mg q24W -69 µm Difference +10 µm letters Loading phase (all arms)
Slide 25: Pooled Safety Favorable with Redosing
Preliminary data – pending final analysis Subjects with Ocular AEs in Study Eye ≥2% through Week 56 DURAVYU 2.7mg (n=443) Aflibercept 2mg (n=464) Conjunctival haemorrhage 10.2% 4.3% Vitreous floaters 8.6% 2.8% Neovascular age-related macular degeneration 5.9% 1.7% Retinal haemorrhage 4.7% 1.5
Slide 26: Review of DME Program
@ EvePoint Review of DME Program “—_
Slide 27: COMO and CAPRI: Phase 3 DME Program
COMO and CAPRI: Phase 3 DME Program Designed to Enable Potential Global Regulatory and Commercial Success First patients dosed in both trials in February 2026 Full enrollment in July 2026 Topline data expected in 4Q 2027 Key Elements of Phase 3 Trial Design: Informed by positive Phase 2 VERONA trial
Slide 28: Phase 3 Pivotal Trials in DME: Non-Inferiority vs On-Label Aflibercept
Phase 3 Pivotal Trials in DME: Designed to Evaluate Non-Inferiority of DURAVYU vs On-Label Aflibercept Control D1 W4 W8 W12 W161 W20 W24 W28 W32 W36 W40 W44 W48 W52 W56 W60 to W68 W72 W76 to W84 W88 EOS Primary endpoint Blend W52 & W56 DURAVYU 2.7 mg Aflibercept 2 mg q8W DURAVYU dosing DURAVYU dosin
Slide 29: Phase 2 VERONA: Single DURAVYU 2.7mg Treatment Vision and Anatomical Improvement
DURAVYU 2.7mg +2.8 letters* Phase 2 VERONA: Single DURAVYU 2.7mg Treatment Demonstrated Meaningful Vision and Anatomical Improvement as Early as Week 4 BCVA, best-corrected visual acuity; CST, central subfield thickness; ETDRS, Early Treatment Diabetic Retinopathy Study;. VERONA Clinicaltrials.gov I
Slide 30: Dose-Dependent Reduction in Macular Leakage Area in DME
Dose-Dependent Reduction in Macular Leakage Area with a Single DURAVYU Injection in DME Illustrative patient case; not representative of all observed cases or predictive of treatment outcomes 1. Change from baseline in vascular leakage (mm2) in the macula and in the total retinal area. Full analysis
Slide 31: Continued Drying with Improved BCVA After a Single DURAVYU Dose
Continued Drying at Week 24 with Improved BCVA After a Single DURAVYU 2.7mg Dose and No Supplementation Illustrative patient case; not representative of all observed cases or predicative of treatment outcomes. BCVA, best-corrected visual acuity; CST, central subfield thickness; D, day; VA, visual ac
Slide 32: Conclusions & Next Steps
@ EvePoint Conclusions & Next Steps “—_
Slide 33: Summary
Summary LUCIA did not meet primary endpoint of mean change in BCVA, despite visual improvement Meaningful reduction in treatment burden (nominal p-value <0.0001) with strong anatomic control demonstrates activity of DURAVYU Continued favorable safety profile with redosing Additional analyses ongoing
Slide 34: LUCIA Phase 3 Clinical Trial DURAVYU in Wet AMD Topline Results
LUCIA Phase 3 Clinical Trial DURAVYU in Wet AMD Topline Results | October 2026